Previous close | 4.8250 |
Open | 4.8000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 4.8000 - 4.9550 |
52-week range | 4.0450 - 13.1600 |
Volume | |
Avg. volume | 46,727 |
Market cap | 79.414M |
Beta (5Y monthly) | 1.80 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.3400 |
Earnings date | 20 Apr 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 33.60 |
SOPHIA ANTIPOLIS, France, June 01, 2023--Median Technologies to participate in the 2023 ASCO Annual Meeting, June 2-6, 2023, McCormick Place, Chicago, IL, USA
SOPHIA ANTIPOLIS, France, May 30, 2023--Median Technologies announces the availability of the preparatory documents for the Shareholders’ Ordinary and Extraordinary GM on June 20, 2023
SOPHIA ANTIPOLIS, France, May 10, 2023--Regulatory News: Median Technologies (Paris:ALMDT):
SOPHIA-ANTIPOLIS, France, April 25, 2023--Median Technologies reschedules its Corporate Update webcasts on May 4, 2023.
SOPHIA-ANTIPOLIS, France, April 24, 2023--Median Technologies to host two webcasts and provide a company update on May 3, 2023.
SOPHIA ANTIPOLIS, France, April 20, 2023--Median Technologies reports full-year 2022 results and business indicators for the first quarter of 2023.
SOPHIA ANTIPOLIS, France, April 06, 2023--Regulatory News: Median Technologies (Paris:ALMDT):
SOPHIA ANTIPOLIS, France, March 07, 2023--Regulatory News: Median Technologies (Paris:ALMDT):
SOPHIA ANTIPOLIS, France, February 28, 2023--Regulatory News: Median Technologies (ALMDT:PA) today announces new and breakthrough results for its iBiopsy® Lung Cancer Screening (LCS) AI/ML tech-based CADe/CADx1 Software as Medical Device (SaMD) to characterize malignant lung nodules in low dose CT scans (LDCT).
SOPHIA-ANTIPOLIS, France, February 27, 2023--Regulatory News: Median Technologies (ALMDT) (Paris:ALMDT) announces today that the Company has received feedback from the United States Food and Drug Administration (FDA) regarding the Q-submission phase initiated on May 2, 2022 for its iBiopsy® Lung Cancer Screening (LCS) AI/ML tech-based CADe/CADx1 Software as Medical Device (SaMD) and announces completion of this phase.
SOPHIA ANTIPOLIS, France, February 23, 2023--Regulatory News: Median Technologies (Paris:ALMDT), will be participating in the Cowen’s 43rd Annual Health Care Conference, taking place on March 6 – 8 ,2023, at the Boston Marriott Copley Place in Boston, MA, USA.
SOPHIA ANTIPOLIS, France, February 08, 2023--Regulatory News: Median Technologies (Paris:ALMDT):
SOPHIA-ANTIPOLIS, France, January 24, 2023--Median Technologies to host two webcasts and provide a company update on February 2, 2023.
SOPHIA ANTIPOLIS, France, January 19, 2023--Median Technologies announces 2022 revenue of €23.8 million, up 16%, and an order backlog of €60.8 million.
SOPHIA ANTIPOLIS, France, January 09, 2023--Regulatory News: Under the liquidity contract entrusted by Median Technologies (FR0011049824 – ALMDT FP) (Paris:ALMDT) to TP ICAP (Europe), the following resources were listed in the liquidity account as of 12/31/2022:
SOPHIA ANTIPOLIS, France, January 06, 2023--Regulatory News: Median Technologies (Paris:ALMDT):
SOPHIA ANTIPOLIS, France, December 21, 2022--Financial Communications Schedule for the First Half of 2023
SOPHIA ANTIPOLIS, France, December 06, 2022--Disclosure of total number of voting rights and number of shares in the capital as of November 30th, 2022.
SOPHIA ANTIPOLIS, France, November 23, 2022--Median Technologies announces the availability of the preparatory documents for the Shareholders’ Extraordinary General Meeting on December 9, 2022.
SOPHIA ANTIPOLIS, France, November 22, 2022--Median Technologies to speak at the Radiological Society of North America (RSNA) 2022 Annual Meeting, Nov. 27 - Dec 1, Chicago, IL, USA.
SOPHIA ANTIPOLIS, France, November 08, 2022--Droits de vote d'octobre
SOPHIA ANTIPOLIS, France, October 20, 2022--Regulatory News: Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT), whose Board of Directors approved on October 18, 2022 the consolidated IFRS financial statements for the first half of 2022 after a limited review, announces today its half-year results as well as revenues for the third quarter of 2022.
SOPHIA ANTIPOLIS, France, October 05, 2022--Regulatory News: Median Technologies (Paris:ALMDT):
SOPHIA-ANTIPOLIS, France, October 03, 2022--Regulatory News: Median Technologies (Paris:ALMDT) announced today the formation of their Clinical Advisory Board (CAB) for iBiopsy® Lung Cancer Screening. This group of world class physicians brings comprehensive expertise in the space of Lung Cancer Screening to guide Median in the development of iBiopsy® LCS AI/ML tech-based CADe/CADx SaMD (software as medical device), which detects and characterizes lung cancer nodules in high risk populations, ult
SOPHIA ANTIPOLIS, France, September 09, 2022--Regulatory News: Median Technologies (Paris:ALMDT):